SCHEMBL402070

SCHEMBL402070

COCCC(CO)OC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8689223 0.86 CYP2C9 (0.32)
SCHEMBL19257460 0.84 CYP2C9 (0.41)
SCHEMBL12580946 0.83 CYP2C9 (0.30)
SCHEMBL28410830 0.83 ALDH1A1 (0.35)
SCHEMBL19257464 0.83 TSHR (0.41)
SCHEMBL27782220 0.83 TSHR (0.41)
SCHEMBL7094163 0.83
SCHEMBL5719 0.80
SCHEMBL14007344 0.80
SCHEMBL6041979 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022140-A1 Method of treating a cancer with a survivin antisense oligonucleotide and paclitaxel ELI LILLY AND COMPANY (US) 2012-01-26 US disclosed
US-6117999-A Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors AGOURON PHRAMACEUTICALS, INC. (US) 2000-09-12 US disclosed
US-4859759-A Siloxane containing benzotriazolyl/tetraalkylpiperidyl substituent KIMBERLY-CLARK CORPORATION (US) 1989-08-22 US disclosed